Category: Home

Insulin analogues

Insulin analogues

Insulin analogues and Histopathological Risk Factors for Radioactive Iodine Analoguew Follicular and Oncocytic Thyroid Carcinoma. Anaoogues causes Sports nutrition for runners vasodilation, analoyues well Insulin analogues, and results in faster absorption of insulin lispro. The crystal structure of insulin lispro was determined as a T 3 R f 3 zinc hexamer containing 3 bound phenolic analoguss whereas the structure of analoguse aspart was determined as an R 6 hexamer containing 6 bound ligands. J Biol Chem. Read More About Diabetes Diabetes and Endocrinology Clinical Pharmacy and Pharmacology Pharmacoeconomics. They are given at mealtimes and for high blood sugar correction. Previous Article Next Article.

Insulin analogues -

Dodson G , Steiner D. Curr Opin Struct Biol. Baker EN , Blundell TL , Cutfield JF , et al. The structure of 2Zn pig insulin crystals at 1. Philos Trans R Soc Lond B Biol Sci. Lawrence MC. Understanding insulin and its receptor from their three-dimensional structures.

Mol Metab. Brange J. Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations.

Jeitler K , Horvath K , Berghold A , et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Freckmann G , Buck S , Waldenmaier D , et al. Insulin pump therapy for patients with type 2 diabetes mellitus: evidence, current barriers, and new technologies.

J Diabetes Sci Technol. Boscari F , Avogaro A. Current treatment options and challenges in patients with type 1 diabetes: pharmacological, technical advances and future perspectives.

Rev Endocr Metab Disord. Woods RJ , Alarcón J , McVey E , Pettis RJ. Intrinsic fibrillation of fast-acting insulin analogs. Krasner A , Pohl R , Simms P , Pichotta P , Hauser R , De Souza E.

A review of a family of ultra-rapid-acting insulins: formulation development. Owens DR , Bolli GB. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.

Falk BT , Liang Y , McCoy MA. Profiling insulin oligomeric states by 1 H NMR spectroscopy for formulation development of ultra-rapid-acting insulin. J Pharm Sci. Boughton CK , Hartnell S , Thabit H , et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study.

Ciszak E , Beals JM , Frank BH , Baker JC , Carter ND , Smith GD. Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProBhuman insulin. Whittingham JL , Edwards DJ , Antson AA , Clarkson JM , Dodson GG. Hua QX , Shoelson SE , Kochoyan M , Weiss MA.

Receptor binding redefined by a structural switch in a mutant human insulin. Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue. J Mol Biol. Olsen HB , Ludvigsen S , Kaarsholm NC.

Solution structure of an engineered insulin monomer at neutral pH. Jacoby E , Hua QX , Stern AS , Frank BH , Weiss MA. Structure and dynamics of a protein assembly. Bentley G , Dodson E , Dodson G , Hodgkin D , Mercola D.

Structure of insulin in 4-zinc insulin. Derewenda U , Derewenda Z , Dodson EJ , et al. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Gillis RB , Solomon HV , Govada L , et al. Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques.

Sci Rep. Warren M , Bode B , Cho JI , et al. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump Berenson DF , Weiss AR , Wan ZL , Weiss MA.

Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. Ann N Y Acad Sci. Levin P , Hoogwerf BJ , Snell-Bergeon J , Vigers T , Pyle L , Bromberger L.

Ultra rapid-acting inhaled insulin improves glucose control in patients with type 2 diabetes mellitus. Endocr Pract. Paavola CD , Cox AL , Sperry AE , et al. A stable, hexameric, ultra-rapid insulin formulation containing citrate. Paper presented at: Diabetes ; 66 : A Meiffren G , Plum-Moerschel L , Ranson A , et al.

BioChaperone BC , the new excipient enabling the ultra-rapid BioChaperone Lispro BCLIS formulation, is completely absorbed and rapidly excreted after subcutaneous s.

doi: Heise T , Meiffren G , Alluis B , et al. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomized euglycemic clamp study.

Haahr H , Heise T. Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences.

Clin Pharmacokinet. Blevins T , Zhang Q , Frias JP , Jinnouchi H , Chang AM ; PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D.

Linnebjerg H , Zhang Q , LaBell E , et al. Pharmacokinetics and glucodynamics of ultra rapid lispro URLi versus Humalog Lispro in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. Pratt E , Leohr J , Heilmann C , Johnson J , Landschulz W.

Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro. Mann JL , Maikawa CL , Smith AA , et al. An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients.

Sci Transl Med. Engineering biopharmaceutical formulations to improve diabetes management. Dornhorst A , Lüddeke HJ , Sreenan S , et al. Farag YM , Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. Levien TL , Baker DE , White JR , Campbell RK. Insulin glargine: a new basal insulin.

Ann Pharmacother. Schade DS , Eaton RP , DeLongo J , Saland LC , Ladman AJ , Carlson GA. Electron microscopy of insulin precipitates. Bolli GB , Hahn AD , Schmidt R , et al.

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Steinstraesser A , Schmidt R , Bergmann K , Dahmen R , Becker RH. Becker RH , Dahmen R , Bergmann K , Lehmann A , Jax T , Heise T.

Owens DR. Expert Opin Drug Metab Toxicol. Werner U , Tennagels N , Fanelli CG , Bolli GB. de Galan BE. Patient Prefer Adherence.

Havelund S , Plum A , Ribel U , et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir.

Int J Obes Relat Metab Disord. Frier BM , Russell-Jones D , Heise T. A comparison of insulin detemir and neutral protamine Hagedorn isophane insulin in the treatment of diabetes: a systematic review.

Heise T , Nosek L , Rønn BB , et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Tone A , Iseda I , Higuchi C , et al. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.

Exp Clin Endocrinol Diabetes. Meneghini L , Kesavadev J , Demissie M , Nazeri A , Hollander P. Once-daily initiation of basal insulin as add-on to metformin: a week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.

Steensgaard DB , Schluckebier G , Strauss HM , et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec.

Kurtzhals P , Havelund S , Jonassen I , et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Jonassen I , Havelund S , Hoeg-Jensen T , Steensgaard DB , Wahlund PO , Ribel U.

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Battelino T , Edelman SV , Nishimura R , Bergenstal RM.

Comparison of second-generation basal insulin analogs: a review of the evidence from continuous glucose monitoring. Diabetes Technol Ther. Heise T , Hermanski L , Nosek L , Feldman A , Rasmussen S , Haahr H.

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Ratner RE , Gough SC , Mathieu C , et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Heise T , Nørskov M , Nosek L , Kaplan K , Famulla S , Haahr HL. Heise T , Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Aye MM , Atkin SL. Patient safety and minimizing risk with insulin administration—role of insulin degludec.

Drug Healthc Patient Saf. Demir T , Turan S , Unluhizarci K , Topaloglu O , Tukek T , Gogas Yavuz D. Lau J , Bloch P , Schäffer L , et al.

Discovery of the once-weekly glucagon-like peptide-1 GLP-1 analogue semaglutide. J Med Chem. Cheang JY , Moyle PM. Glucagon-like peptide-1 GLP-1 -based therapeutics: current status and future opportunities beyond type 2 diabetes.

Nauck MA , Wefers J , Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Rosenstock J , Bajaj HS , Janež A , et al.

Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. Bajaj HS , Bergenstal RM , Christoffersen A , et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial.

Kjeldsen TB , Hubálek F , Hjørringgaard CU , et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. Nakagawa SH , Tager HS. Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects.

J Biol Chem. Mirmira RG , Nakagawa SH , Tager HS. Importance of the character and configuration of residues B24, B25, and B26 in insulin-receptor interactions. Ludvigsen S , Roy M , Thøgersen H , Kaarsholm NC.

Ludvigsen S , Olsen HB , Kaarsholm NC. A structural switch in a mutant insulin exposes key residues for receptor binding.

Kjeldsen TB , Hubálek F , Tagmose TM , et al. Engineering of orally available, ultralong-acting insulin analogues: discovery of OI and OI Baghban Taraghdari Z , Imani R , Mohabatpour F. A review on bioengineering approaches to insulin delivery: a pharmaceutical and engineering perspective.

Macromol Biosci. Moore MC , Smith MS , Sinha VP , et al. Novel PEGylated basal insulin LY has a preferential hepatic effect on glucose metabolism. Sinha VP , Howey DC , Choi SL , Mace KF , Heise T.

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY dosed once-daily in patients with type 2 diabetes mellitus. Hedrington MS , Davis SN. Discontinued drug therapies to treat diabetes in Expert Opin Investig Drugs.

Hirose T. Development of new basal insulin peglispro LY ends in a disappointing result. Diabetol Int. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. Jafari R , Zolbanin NM , Rafatpanah H , Majidi J , Kazemi T.

Fc-fusion proteins in therapy: an updated view. Curr Med Chem. Kuo TT , Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. Heise T , Chien J , Beals J , et al. Basal Insulin Fc BIF , a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus.

J Endocr Soc. Wronkowitz N , Hartmann T , Görgens SW , et al. LAPS insulin a novel ultra-long-acting basal insulin with a unique action profile. Production of a novel heterodimeric two-chain insulin-Fc fusion protein.

Protein Eng Des Sel. Insulin preparations. In: Galenics of Insulin. Springer ; : 17 - Roach P , Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.

Yudkin JS. Beran D , Ewen M , Laing R. Constraints and challenges in access to insulin: a global perspective. Cefalu WT , Dawes DE , Gavlak G , et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Keating GM.

Drugs Ther Perspect. Hirsch IB , Franek E , Mersebach H , Bardtrum L , Hermansen K. Diabet Med. Mehta R , Chen R , Hirose T , et al. Janež A , Guja C , Mitrakou A , et al.

Insulin therapy in adults with type 1 diabetes mellitus: a narrative review. Billion L , Charleer S , Verbraeken L , et al. Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring.

Glidden MD , Aldabbagh K , Phillips NB , et al. An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein. Weiss MA. Design of ultra-stable insulin analogues for the developing world.

J Health Spec. Diabetes care in the hospital: Standards of Medical Care in Diabetes— Moreira RO , Cobas R , Lopes Assis Coelho RC.

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr. Nuffer W , Guesnier A , Trujillo JM.

Ther Adv Endocrinol Metab. Rodbard HW , Lingvay I , Reed J , et al. Semaglutide added to basal insulin in type 2 diabetes SUSTAIN 5 : a randomized, controlled trial.

J Clin Endocrinol Metab. Perreault L , Rodbard H , Valentine V , Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Adv Ther. Castellana M , Cignarelli A , Brescia F , Laviola L , Giorgino F.

GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis.

Diabetes Metab Res Rev. Huthmacher JA , Meier JJ , Nauck MA. Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis. Frias JP , Chien J , Zhang Q , et al.

Once weekly basal insulin Fc BIF is safe and efficacious in patients with type 2 diabetes mellitus T2DM previously treated with basal insulin. Riddle MC , Nahra R , Han J , et al.

Control of postprandial hyperglycemia in type 1 diabetes by hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study. Riddle MC. Rediscovery of the second β-cell hormone: co-replacement with pramlintide and insulin in type 1 diabetes.

Haidar A , Tsoukas MA , Bernier-Twardy S , et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. VandenBerg MA , Webber MJ. Biologically inspired and chemically derived methods for glucose-responsive insulin therapy.

Adv Healthc Mater. Hoeg-Jensen T. Review: glucose-sensitive insulin. James TD , Sandanayake KRAS , Shinkai S. Saccharide sensing with molecular receptors based on boronic acid. Angew Chem Int Ed Engl.

Springsteen G , Wang B. A detailed examination of boronic acid—diol complexation. Hoeg-Jensen T , Ridderberg S , Havelund S , et al. J Pept Sci. Chou DH , Webber MJ , Tang BC , et al. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.

Proc Natl Acad Sci U S A. Kruse T , Kofoed-Hansen M , Muenzel MWB , et al. Glucose-sensitive albumin-binding derivatives. October 15, Peters JA. Interactions between boric acid derivatives and saccharides in aqueous media: structures and stabilities of resulting esters. Coord Chem Rev.

Boronic acid sensors with double recognition sites: a review. Recent progress in design and preparation of glucose-responsive insulin delivery systems.

J Control Release. Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. Development of shell cross-linked nanoparticles based on boronic acid-related reactions for self-regulated insulin delivery.

J Biomater Sci Polym Ed. Inhibitor discovery for the human GLUT1 from homology modeling and virtual screening. ACS Chem Biol. A forskolin-conjugated insulin analog targeting endogenous glucose-transporter for glucose-responsive insulin delivery.

Biomater Sci. Kaarsholm NC , Lin S , Yan L , et al. Engineering glucose responsiveness into insulin. Krug AW , Visser SAG , Tsai K , et al. Clinical evaluation of MK an insulin analog with glucose-responsive properties.

Clin Pharmacol Ther. Chen YS , Gleaton J , Yang Y , et al. Insertion of a synthetic switch into insulin provides metabolite-dependent regulation of hormone-receptor activation. Proc Natl Acad Sci USA. Menting JG , Yang Y , Chan SJ , et al.

Protective hinge in insulin opens to enable its receptor engagement. Dobbins RL , Connolly CC , Neal DW , Palladino LJ , Parlow AF , Cherrington AD. Role of glucagon in countering hypoglycemia induced by insulin infusion in dogs.

Am J Physiol. Steiner KE , Williams PE , Lacy WW , Cherrington AD. Effects of insulin on glucagon-stimulated glucose production in the conscious dog. Rivera N , Ramnanan CJ , An Z , et al.

Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. J Clin Invest. Bode BW , Boyd J , Shah A , Parkes D , Ghosh S , Cherrington AD.

Pedersen C , Bouman SD , Porsgaard T , Rosenkilde MM , Roed NK. Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats. Physiol Rep.

Pedersen C , Porsgaard T , Thomsen M , Rosenkilde MM , Roed NK. Sustained effect of glucagon on body weight and blood glucose: assessed by continuous glucose monitoring in diabetic rats.

PLoS One. Yang Q , Vijayakumar A , Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol. Kahn BB. Adipose tissue, inter-organ communication, and the path to type 2 diabetes: the Banting Medal for Scientific Achievement Lecture.

Santoro A , McGraw TE , Kahn BB. Insulin action in adipocytes, adipose remodeling, and systemic effects. Cell Metab. Shao J , Zaro JL , Shen WC. Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.

Tissue Barriers. Caparrotta TM , Evans M. PEGylated insulin Lispro, LY —a new basal insulin analogue. Jacober SJ , Prince MJ , Beals JM , et al. Basal insulin peglispro: overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.

Areias MF , Prada PO. Mechanisms of insulin resistance in the amygdala: influences on food intake. Behav Brain Res. Mitchell CS , Begg DP. The regulation of food intake by insulin in the central nervous system.

J Neuroendocrinol. Grattan DR , Andrews ZB. Insulin as a neuroendocrine hormone. Belsham DD , Dalvi PS. Insulin signalling in hypothalamic neurones. Petrovich GD , Setlow B , Holland PC , Gallagher M.

Amygdalo-hypothalamic circuit allows learned cues to override satiety and promote eating. J Neurosci. Hallschmid M , Jauch-Chara K , Korn O , et al. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.

Tsuneki H , Yoshida H , Endo K , et al. Different impacts of acylated and non-acylated long-acting insulin analogs on neural functions in vitro and in vivo.

Diabetes Res Clin Pract. Hölscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Scherer T , Sakamoto K , Buettner C. Brain insulin signalling in metabolic homeostasis and disease.

Heidenreich KA , Zahniser NR , Berhanu P , Brandenburg D , Olefsky JM. Structural differences between insulin receptors in the brain and peripheral target tissues. Ferreira ST. Choi CHJ , Cohen P. Adipose crosstalk with other cell types in health and disease.

Cao H , Gerhold K , Mayers JR , Wiest MM , Watkins SM , Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Yore MM , Syed I , Moraes-Vieira PM , et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects.

Turpin SM , Nicholls HT , Willmes DM , et al. Obesity-induced CerS6-dependent C ceramide production promotes weight gain and glucose intolerance. Raichur S , Brunner B , Bielohuby M , et al. The role of C ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

Whalen EJ , Rajagopal S , Lefkowitz RJ. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. Rajagopal S , Rajagopal K , Lefkowitz RJ.

Teaching old receptors new tricks: biasing seven-transmembrane receptors. Smith JS , Nicholson LT , Suwanpradid J , et al. Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.

Sci Signal. Congreve M , de Graaf C , Swain NA , Tate CG. Impact of GPCR structures on drug discovery. Machelska H , Celik MÖ. Opioid receptors in immune and glial cells—implications for pain control.

Front Immunol. Brown MS , Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Rodríguez-Flores M , García-García E , Cano-Nigenda CV , Cantú-Brito C. Relationship of obesity and insulin resistance with the cerebrovascular reactivity: a case control study.

Sekizkardes H , Chung ST , Chacko S , et al. Free fatty acid processing diverges in human pathologic insulin resistance conditions. Saltiel AR , Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Rahman I , Athar MT , Islam M. Type 2 diabetes, obesity, and cancer share some common and critical pathways.

Front Oncol. Krüger M , Kratchmarova I , Blagoev B , Tseng YH , Kahn CR , Mann M. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Kalita B , Bano S , Vavachan VM , Taunk K , Seshadri V , Rapole S.

Application of mass spectrometry based proteomics to understand diabetes: a special focus on interactomics. Biochim Biophys Acta Proteins Proteom. Pillutla RC , Hsiao KC , Beasley JR , et al. Peptides identify the critical hotspots involved in the biological activation of the insulin receptor.

Jensen M , Palsgaard J , Borup R , de Meyts P , Schäffer L. Activation of the insulin receptor IR by insulin and a synthetic peptide has different effects on gene expression in IR-transfected L6 myoblasts. Lawrence CF , Margetts MB , Menting JG , et al.

Insulin mimetic peptide disrupts the primary binding site of the insulin receptor. Bacon K , Blain A , Burroughs M , McArthur N , Rao BM , Menegatti S.

Isolation of chemically cyclized peptide binders using yeast surface display. ACS Comb Sci. Iskandar SE , Haberman VA , Bowers AA. Expanding the chemical diversity of genetically encoded libraries. Bowen J , Schneible J , Bacon K , Labar C , Menegatti S , Rao BM. Screening of yeast display libraries of enzymatically treated peptides to discover macrocyclic peptide ligands.

Int J Mol Sci. Jeong MY , Rutter J , Chou DH. Display of single-chain insulin-like peptides on a yeast surface. A clinical approach to severe insulin resistance. Endocr Dev. Schloot NC , Hood RC , Corrigan SM , Panek RL , Heise T.

Concentrated insulins in current clinical practice. Sun G , Kashyap SR. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.

J Nutr Metab. Kurtzhals P , Schäffer L , Sørensen A , et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Currie CJ , Poole CD , Gale EA.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. But A , De Bruin ML , Bazelier MT , et al. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.

Versteyhe S , Klaproth B , Borup R , et al. IGF-I, IGF-II, and insulin stimulate different gene expression responses through binding to the IGF-I receptor. Hirsch IB , Juneja R , Beals JM , Antalis CJ , Wright EE Jr.

The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. Pettus JH , Kushner JA , Valentine V , et al. Adjunct therapy in type 1 diabetes: a survey to uncover unmet needs and patient preferences beyond HbA1c measures.

Powers MA , Bardsley JK , Cypress M , et al. Sci Diabetes Self Manag Care. Home P. The evolution of insulin therapy. Future directions in insulin therapy. Bally L , Thabit H , Hovorka R. Glucose-responsive insulin delivery for type 1 diabetes: the artificial pancreas story.

Int J Pharm. Beran D , Lazo-Porras M , Mba CM , Mbanya JC. A global perspective on the issue of access to insulin. Heinemann L , Braune K , Carter A , Zayani A , Krämer LA. Insulin storage: a critical reappraisal. Meis CM , Salzman EE , Maikawa CL , et al.

Self-assembled, dilution-responsive hydrogels for enhanced thermal stability of insulin biopharmaceuticals. ACS Biomater Sci Eng. Khedkar A , Lebovitz H , Fleming A , et al.

Pharmacokinetics and pharmacodynamics of insulin tregopil in relation to premeal dosing time, between meal interval, and meal composition in patients with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. Kapoor K , Finer-Moore JS , Pedersen BP , et al. Nowadays, insulin analogs are also used to treat diabetes.

Insulin analogs are made in the same way as human insulin but are genetically altered to change the way they act in your body. Insulin analogs have a different chemical structure and lower your blood sugar more quickly once insulin is injected into your body. Pens and syringes are both injected under your skin with a small needle.

The needle in pens tends to be smaller than the needle in syringes. Some pens use cartridges that you insert into the pen manually while others are prefilled and thrown away when empty.

Insulin pumps deliver insulin through a tube placed into the fatty layer under your skin, usually around your stomach or the back of your upper arm. Never reuse syringes, needles, or pens. Doing so can increase your risk of contracting or transmitting a blood-borne illness such as hepatitis or HIV.

The primary benefit of regular human insulin over insulin analogs is the cost. According to an article published in the American Journal of Medicine, insulin prices tripled from to and doubled between to A study found an insignificant difference in the A1C test results between people who switched to human insulin or continued taking insulin analogs.

An A1C test measures average blood sugar levels over the past 3 months. The researchers found better adherence in the human insulin group due to the lower cost. In high concentrations, human and animal insulin tends to clump when injected into the skin. This clumping can cause slow and sporadic absorption.

In comparison, insulin analogs tend to clump less and are absorbed more predictably. Human insulin tends to take effect slower than insulin analogs. Insulin analogs can start acting in as little as 5 to 10 minutes after injection.

Regular human insulin takes about 15 to 30 minutes to start working after being injected. A group of insulin analogs called long-acting insulin analogs or basal insulins can act for up to 24 hours and require fewer injections than human insulin. Your insulin regimen needs to be tailored to your specific lifestyle and overall health in order to keep your blood sugar levels regulated as effectively as possible.

Human insulin is synthetically made in a lab using E. It replicates the insulin naturally found in your body. Until the commercial availability of human insulin in the late s, animal-derived insulin was used to help people manage diabetes.

Insulin analogs, a subgroup of human insulin, are also used to treat diabetes, but are genetically altered to change the way they act in your body. Insulin analogs tend to take effect more quickly than human insulin, but are often more expensive.

Different people have different needs when it comes to insulin. Our experts continually monitor the health and wellness space, and we update our articles when new information becomes available. Diabetes hinders your ability to produce insulin. Without it, cells are starved for energy and must seek an alternate source, leading to serious….

Insulin pens don't eliminate your need to poke yourself with a needle. They make measuring and delivering your insulin easier. Here's what you need to…. Using insulin can be tricky sometimes.

Here are some do's and don'ts to pay attention to as you learn how to effectively manage your diabetes with…. The three P's of diabetes refer to the most common symptoms of the condition. Those are polydipsia, polyuria, and polyphagia. High blood glucose can…. Singer Nick Jonas, who has type 1 diabetes, debuted a new blood glucose monitoring device during a Super Bowl television commercial.

Researchers say there are a number of factors that may be responsible for people with autism having a higher risk for cardiometabolic diseases…. A Quiz for Teens Are You a Workaholic? How Well Do You Sleep? Health Conditions Discover Plan Connect.

What to Know About Human Insulin and How It Works. Medically reviewed by Michelle L. Griffith, MD — By Daniel Yetman on October 27, What is human insulin? What are the advantages of human insulin?

In type analoguds diabetes mellitus, progressive loss of beta cells Ibsulin in the disruption of Nutrition tips for fitness insulin secretion, in turn leading to requirement for insulin Type diabetes blood sugar levels. Considering that the Insulin analogues Insuulin of normal anqlogues secretion is complex, close Inuslin of this Type diabetes blood sugar levels is Lycopene and exercise performance to address both fasting and prandial glucose control. In analogue insulin preparations, such as regular human insulin RHIinsulin molecules typically self-aggregate to form dimers, which in turn stabilize around zinc ions to form hexamers. The dissociation of hexamers into dimers and monomers is a rate-limiting step in absorption for all insulins and contributes to the delay in the effect of RHI. Because insulin hexamers are too bulky to be transported across the vascular endothelium, there is a to minute lag phase between injection and onset of action, which requires careful dose administration and food consumption. Exogenous basal insulin delivery has traditionally involved single or twice-daily injections of neutral protamine Hagedorn NPH insulin, which is a formulation of protamine insulin in a zinc suspension. Protamine prolongs the absorption of NPH insulin, causing an intermediate duration of action ha significant peak in action hand an unpredictable profile of insulin absorption and activity. Insulin analogues

Author: Nikorg

5 thoughts on “Insulin analogues

  1. Ich entschuldige mich, aber meiner Meinung nach sind Sie nicht recht. Ich biete es an, zu besprechen. Schreiben Sie mir in PM, wir werden umgehen.

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com